Home › Funds › PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. › RPRX

PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. position in RPRX

ROYALTY PHARMA PLC · Health Care

PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. reported holding 510,625 shares of RPRX (ROYALTY PHARMA PLC) in its Q3 2026 13F filing — a position valued at US$29.8M, representing 1.51% of its reported portfolio and ranking #17 among its reported holdings. PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. has disclosed RPRX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)510.62K sh
Reported value held$29.80M
Portfolio Weight1.51%
First reportedQ1 2024
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.'s RPRX position evolved

PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. first disclosed a stake in RPRX in Q1 2024 at 368,916 shares (US$11.2M). The position peaked in Q2 2026 at 597,938 shares, worth US$33.5M. Across 11 filings, PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. increased the stake 6 time(s), trimmed it 1 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 510,625 shares valued at US$29.8M — a reduction of -87,313 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q1 2024 368.92K $11.20M New
Q2 2024 424.54K $11.20M Add
Q3 2024 461.05K $13.04M Add
Q4 2024 472.21K $12.05M Add
Q1 2025 573.60K $17.86M Add
Q2 2025 595.96K $21.47M Add
Q3 2025 595.89K $21.02M Hold
Q4 2025 600.17K $23.19M Add
Q1 2026 598.62K $28.72M Hold
Q2 2026 597.94K $33.53M Hold
Q3 2026 510.62K $29.80M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RPRX and 13F data

RPRX (ROYALTY PHARMA PLC) is a Health Care company. 47 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$598.8M), Baillie Gifford & Co (US$534.1M), ROYAL LONDON ASSET MANAGEMENT LTD (US$348.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RPRX

All RPRX fund holders →

FAQ

How long has PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. held RPRX?

PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. has disclosed RPRX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

What is PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.'s current position in RPRX?

As of Q3 2026, PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. holds 510.62K shares of RPRX (ROYALTY PHARMA PLC), valued at $29.80M, representing 1.51% of its reported portfolio and ranking #17.

Has PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. been buying or selling RPRX?

In the latest 13F filing (Q3 2026), PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. reduced its position in RPRX. The position peaked in Q2 2026 at 597.94K shares.

Which other funds hold RPRX?

Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, ROYAL LONDON ASSET MANAGEMENT LTD, among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.